Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Primary research

Celastrol induces apoptosis of gastric cancer cells by miR-146a inhibition of NF-κB activity

Authors: Min Sha, Jun Ye, Li-xin Zhang, Zheng-yun Luan, Ya-bao Chen

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Background

Celastrol, a plant triterpene, is known to play important role in inhibiting proliferation and inducing apoptosis of gastric cancer cells. In the present study, the mechanism of celastrol on gastric cancer cells apoptosis was examined.

Methods

We assessed effect of celastrol on NF-κB signaling pathway in gastric cancer cells using western blot and luciferase reporter assay. The real-time PCR was used to evaluate the effect of celastrol on miR-146a expression, and miR-146a mimic to evaluate whether over-expression of miR-146a can affect NF-κB activity. Finally, the effect of miR-146a on celastrol-induced anti-tumor activity was assessed using miR-146a inhibitor.

Results

Celastrol decreased gastric cancer cells viability in a dose-dependent. Celastrol also reduced IκB phosphorylation, nuclear P65 protein levels and NF-κB activity. Furthermore, Celastrol could increase miR-146a expression and up-regulation of miR-146a expression could suppress NF-κB activity. More important, down-regulation of miR-146a expression can reverse the effect of celastrol on NF-κB activity and apoptosis in gastric cancer cells.

Conclusions

In this study, we demonstrated that the effect of celastrol on apoptosis is due to miR-146a inhibition of NF-κB activity.
Appendix
Available only for authorised users
Literature
1.
Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ: Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008, 9 (3): 279-287. 10.1016/S1470-2045(08)70072-X.CrossRefPubMed
2.
3.
Salminen A, Lehtonen M, Paimela T, Kaarniranta K: Celastrol: molecular targets of thunder God vine. Biochem Biophys Res Commun. 2010, 394 (3): 439-442. 10.1016/j.bbrc.2010.03.050.CrossRefPubMed
4.
Morita T: Celastrol: a new therapeutic potential of traditional Chinese medicine. Am J Hypertens. 2010, 23 (8): 821-10.1038/ajh.2010.87.CrossRefPubMed
5.
Kannaiyan R, Shanmugam MK, Sethi G: Molecular targets of celastrol derived from thunder of God vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 2011, 303 (1): 9-20. 10.1016/j.canlet.2010.10.025.CrossRefPubMed
6.
Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A, Lam P, Kumar AP, Sethi G: Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis. 2011, 16 (10): 1028-1041. 10.1007/s10495-011-0629-6.CrossRefPubMed
7.
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5.CrossRefPubMed
8.
Winter J, Jung S, Keller S, Gregory RI, Diederich S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009, 11 (3): 228-234. 10.1038/ncb0309-228.CrossRefPubMed
9.
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005, 353 (17): 1793-1801. 10.1056/NEJMoa050995.CrossRefPubMed
10.
Hou Z, Xie L, Yu L, Qian X, Liu B: MicroRNA-146a is down-regulated in gastric cancer and regulates cell proliferation and apoptosis. Med Oncol. 2012, 29 (2): 886-892. 10.1007/s12032-011-9862-7.CrossRefPubMed
11.
Crone SG, Jacobsen A, Federspiel B, Bardram L, Krogh A, Lund AH, Friis-Hansen L: microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer. Mol Cancer. 2012, 11: 71-10.1186/1476-4598-11-71.PubMedCentralCrossRefPubMed
12.
Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M, Katano M: Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res. 2001, 7 (12): 4136-4142.PubMed
13.
14.
Dutta J, Fan Y, Gupta N, Fan G, Gélinas C: Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 2006, 25 (51): 6800-6816. 10.1038/sj.onc.1209938.CrossRefPubMed
15.
Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, Hong YS, Lee JJ: Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol. 2006, 72 (10): 1311-1321. 10.1016/j.bcp.2006.08.014.CrossRefPubMed
16.
He D, Xu Q, Yan M, Zhang P, Zhou X, Zhang Z, Duan W, Zhong L, Ye D, Chen W: The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer. 2009, 9: 343-10.1186/1471-2407-9-343.PubMedCentralCrossRefPubMed
17.
Chen LF, Greene WC: Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol. 2004, 5 (5): 392-401. 10.1038/nrm1368.CrossRefPubMed
18.
Wang XN, Wu Q, Yang X, Zhang LS, Wu YP, Lu C: Effects of Celastrol on growth inhibition of U937 leukemia cells through the regulation of the Notch1/NF-kappaB signaling pathway in vitro. Chin J Cancer. 2010, 29 (4): 385-390. 10.5732/cjc.009.10526.CrossRefPubMed
19.
Zhou LL, Lin ZX, Fung KP, Cheng CH, Che CT, Zhao M, Wu SH, Zuo Z: Celastrol-induced apoptosis in human HaCaT keratinocytes involves the inhibition of NF-κB activity. Eur J Pharmacol. 2011, 670 (2–3): 399-408.CrossRefPubMed
20.
Oeckinghaus A, Ghosh S: The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009, 1 (4): a000034-10.1101/cshperspect.a000034.PubMedCentralCrossRefPubMed
21.
Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, Yin HR, Lin YZ: Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2¢-deoxyuridine. World J Gastroenterol. 2004, 10: 172-176.PubMed
22.
Vermes I, Haanen C, Reutelingsperger C: Flow cytometry of apoptotic cell death. J Immunol Methods. 2000, 243: 167-190. 10.1016/S0022-1759(00)00233-7.CrossRefPubMed
Metadata
Title
Celastrol induces apoptosis of gastric cancer cells by miR-146a inhibition of NF-κB activity
Authors
Min Sha
Jun Ye
Li-xin Zhang
Zheng-yun Luan
Ya-bao Chen
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-50

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue

Primary research

Inhibition of the angiogenesis and growth of Aloin in human colorectal cancer in vitro and in vivo

Primary research

Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL

Primary research

Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines

Primary research

CpG oligodeoxynucleotides enhance chemosensitivity of 5-fluorouracil in HepG2 human hepatoma cells via downregulation of the antiapoptotic factors survivin and livin

Primary research

Role of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells

Primary research

Combining the negative lymph nodes count with the ratio of positive and removed lymph nodes can better predict the postoperative survival in cervical cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits